Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

BioMS Medical reports results of exploratory phase II dirucotide trial in MS

Feb. 2, 2009

GSK claims new CGRP receptor antagonists useful for treating migraine and cluster headache

Feb. 2, 2009

Novel sodium channel blockers with analgesic activity developed at AstraZeneca

Feb. 2, 2009

Kv1 potassium channel inhibitors with anxiolytic properties synthesized at Lectus Therapeutics

Feb. 2, 2009

Acrux ceases development of Fentanyl MDTS for chronic pain

Jan. 30, 2009

Cannasat to commence phase Ib CAT-310 study for neuropathic pain

Jan. 30, 2009

Connexin43 mimetic peptide shows promise in spinal cord contusion injury model

Jan. 30, 2009

Roche divulges antipsychotic tachykinin NK3 receptor antagonists

Jan. 30, 2009

Chelsea initiates phase II droxidopa trial in fibromyalgia

Jan. 29, 2009

Cripto blockade enhances embryonic stem cell transplant in Parkinson's disease model

Jan. 29, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...